Medication info
Gavsmate Tablet 50/850 mg

Gavsmate Tablet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Novartis Korea Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP packaging × 6)
Approval status
Active

MFDS item code 200803516 · Approved 2008.03.31 · Insurance code 653601420

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin exceeding 100mg per day are not recommended. This medicine should generally be taken with or immediately after food to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. Gradually increase the dose up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is 100mg of vildagliptin per day and the patient's existing metformin dose. The initial dose of this medicine is determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the existing dose. - When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have examined the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in a type 2 diabetes treatment regimen may alter blood glucose control, so caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at once to make up for the missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment with this medicine.

Ingredients

Importer
Novartis Korea Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used in combination with dietary and exercise therapy to enhance blood glucose control by administering vildagliptin and metformin in patients with type 2 diabetes.

How to take

Adult dose

For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin exceeding 100mg per day are not recommended. This medicine should generally be taken with or immediately after food to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. Gradually increase the dose up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is 100mg of vildagliptin per day and the patient's existing metformin dose. The initial dose of this medicine is determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the existing dose. - When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have examined the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in a type 2 diabetes treatment regimen may alter blood glucose control, so caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at once to make up for the missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment with this medicine.

Precautions

This medication can cause serious lactic acidosis or hypoglycemia, so it should not be used in patients at high risk for these conditions. It should not be administered to patients with significantly reduced kidney function, heart failure, or renal impairment due to acute myocardial infarction or sepsis. If undergoing tests using radiologic iodinated contrast agents, this medication should be discontinued 48 hours before the test and resumed only after confirming normal kidney function. Patients with an allergy to this medication, type 1 diabetes, diabetic ketoacidosis, or metabolic acidosis such as lactic acidosis should not receive this medication. Avoid use in patients with severe infections, severe trauma, malnutrition, liver dysfunction, pulmonary embolism, severe pulmonary dysfunction, excessive alcohol consumption, pregnant or breastfeeding women. Caution should be exercised in cases of irregular meals, intense exercise, or interactions with other medications. During treatment, symptoms such as headache, dizziness, nausea, and hypoglycemia may occur, and if adverse reactions are severe, consultation with a physician is advised. Regular liver function tests should be performed to monitor liver function, and kidney function should also be regularly monitored. Special care is required for the elderly, as they may experience reduced kidney function, necessitating dose adjustment and caution. Alcohol intake may increase the risk of lactic acidosis, so it is advisable to avoid alcohol during treatment. It is necessary to discontinue this medication for a period before and after surgery, and appropriate measures should be taken immediately if hypoglycemic symptoms occur. Women who are pregnant or breastfeeding should not use this medication, and it is also not recommended for children and adolescents under 18 years of age. In case of overdose, supportive therapy is necessary, and hemodialysis may be beneficial. This medication should be kept out of reach of children and should not be transferred to another container.

Side effects

Lactic acidosis, hypoglycemia, hepatitis, abnormal liver function, elevated transaminase levels, angioedema, tremors, headache, dizziness, fatigue, nausea, gastroesophageal reflux, diarrhea, bloating, chills, reduced blood sugar, weakness, hyperhidrosis, constipation, arthralgia, upper respiratory infection, nasopharyngitis, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, decreased appetite, taste disorders, skin reactions (erythema, pruritus, urticaria), pancreatitis, urticaria, blisters, exfoliative skin lesions, severe and disabling arthralgia, cutaneous vasculitis, cholecystitis, dyspepsia, abdominal discomfort, gastrointestinal disturbances, elevated serum amylase, increased lipase, vesicular pemphigoid, myalgia, paresthesia, fever, edema, swelling of the hands and feet, elevated creatine phosphokinase, elevated AST, increased C-reactive protein, elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so the container must be kept tightly sealed. Additionally, it is recommended to store the medication in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP packaging × 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.